ASH 2015: Highs And Lows In CLL
This article was originally published in Scrip
Executive Summary
A number of companies reported positive developments for products being developed for, or seeking label expansions in, chronic lymphatic leukemia (CLL) at the American Society of Hematology (ASH) annual meeting in Orlando, Florida, but Gilead Sciences kept the balance with a poor prognosis for Zydelig (idelalisib) as a future first-line agent.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.